Scientific Overview

PT-141 (Bremelanotide) is a synthetic peptide derived from the melanocortin peptide family, studied in controlled laboratory environments for its interaction with melanocortin receptors and central nervous system signaling pathways.

Within research settings, PT-141 has been explored for its receptor-mediated activity in the brain, particularly in pathways associated with neurochemical signaling and behavioral response models.

Unlike traditional compounds that act through vascular or peripheral mechanisms, PT-141 is characterized by its central mechanism of action, interacting primarily with receptor pathways within the central nervous system.

Mechanism of Action

Research suggests that PT-141 may engage several key biological systems, including:

• Melanocortin receptor activation (MC receptors)
• Central nervous system signaling pathways
• Neurotransmitter modulation mechanisms

These systems are associated with:

• Neural signaling and communication
• Receptor-mediated behavioral responses
• Central regulatory processes
• Neurochemical pathway interaction

PT-141 has been studied for its interaction with melanocortin receptors in the brain, which are involved in a wide range of signaling and regulatory functions within experimental models.

Research Applications

In controlled laboratory environments, PT-141 has been investigated for:

• Receptor signaling pathway research
• Central nervous system studies
• Neurochemical communication analysis
• Behavioral and neurological research models

Research Insights

Preclinical and experimental findings suggest that melanocortin receptor pathways play a significant role in neural signaling and central regulatory processes.

PT-141 continues to be explored for its interaction with these receptor systems, particularly within models focused on central pathway activation and neurochemical signaling dynamics.

Its central mode of action distinguishes it from compounds that primarily act through peripheral systems, positioning it as a compound of interest in receptor-focused research environments.

However, all findings remain within preclinical and experimental frameworks.

Technical Specifications

• Compound: PT-141 (Bremelanotide)
• Quantity: 10 mg
• Form: Lyophilized powder
• Purity: ≥ 99%
• Storage: 2–8°C
• Stability: Protect from light

Research Disclaimer

This product is intended strictly for laboratory research purposes only.
Not for human or animal consumption.

This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.